- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens Ultrasound takes on risk-sharing
While many medical imaging vendors talk about partnering withcustomers, one ultrasound vendor believes that a financial risk-sharingarrangement can also prove profitable. Siemens Ultrasound of Issaquah, WA, announced in January thatit has reached an
While many medical imaging vendors talk about partnering withcustomers, one ultrasound vendor believes that a financial risk-sharingarrangement can also prove profitable.
Siemens Ultrasound of Issaquah, WA, announced in January thatit has reached an equipment purchasing agreement with the ClevelandClinic Foundation that will allow CCF to pay for new scannerson a sliding fee based on equipment usage.
Under the exclusive five-year agreement, Siemens will provideCCF with an entirely new ultrasound department, consisting initiallyof six Sonoline Elegra and two Sonoline Versa ultrasound systems.Siemens will also service and upgrade the new scanners and providemore systems as CCF's needs dictate, according to the company.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
